ETUBICS CORPORATION

Company Information

Company Name
ETUBICS CORPORATION
Address
9715 FREMONT AVE N
SEATTLE, WA, 98103-3140
Phone
n/a
URL
n/a
DUNS
154453018
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,221,335.00
5
SBIR Phase II
$7,323,103.00
3
Chart code to be here

Award List

  1. Improved HIV-Adenoviral Vector Vaccine for Re-immunization

    Amount: $621,380.00

    DESCRIPTION (provided by applicant): The objective of this project is to develop an adenoviral vector vaccine against HIV that is effective in stimulating cell-mediated immunity in animals previously ...

    SBIR Phase I 2006 Department of Health and Human Services
  2. Development of a Novel CEA Expressing Adenovirus for Treatment

    Amount: $112,995.00

    DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immunity in animal ...

    SBIR Phase I 2008 Department of Health and Human Services
  3. Development of a Novel Her2/neu Expressing Adenovirus for Treatment

    Amount: $123,567.00

    DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral serotype 5 (Ad5) vector vaccine against Ad5[E1-, E2b]-Her2/neu that is effective in stimulat ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee

    Amount: $3,353,817.00

    DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of ...

    SBIR Phase II 2009 Department of Health and Human Services
  5. Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment

    Amount: $2,470,285.00

    DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses i ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci

    Amount: $163,405.00

    DESCRIPTION (provided by applicant): The objective of this project is to develop a therapeutic strategy for H V-associated malignancy based on the role of HPV in the pathogenesis. HPV related cancers ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. TAS::75 0849::TAS TOPIC 255 CGMP MANUFACTURE OF A NOVEL HER2/NEU EXPRESSING ADENOVIRUS FOR TREATMENT

    Amount: $199,988.00

    This Phase I, SBIR contract is for the development of a new vaccine targeting HER2/neu expressing breast cancers. The vaccine induces both cell-mediated and humoral immunity and the company is plannin ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. TAS::75 0849- TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING AD5 VIRUS

    Amount: $1,499,001.00

    Etubics Corporation is clinically testing a new vaccine targeting carcinoembryonic antigen (CEA) expressing cancers in a Phase I/II clinical trials under FDA IND14325. Many cancers express CEA, includ ...

    SBIR Phase II 2011 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government